Each reference below was re-fetched from its PubMed record, and the quoted sentence was
confirmed to appear in that abstract and to support the claim it sits under. Follow any of
them to read the source.
Adults with type 2 diabetes received dulaglutide 0.75 mg by subcutaneous injection once weekly for 24 weeks.
Eligible adult patients (≥18 years) with inadequately controlled type 2 diabetes (HbA1c concentration ≥7·0% [53 mmol/mol] and ≤9·5% [80 mmol/mol]), a BMI of 45 kg/m2 or less, and taking stable doses (>3 months) of an SGLT2 inhibitor (with or without metformin) were randomly assigned (1:1:1) via an interactive web-response system to subcutaneous injections of either dulaglutide 1·5 mg, dulaglutide 0·75 mg, or placebo once per week for 24 weeks.
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. The lancet. Diabetes & endocrinology · 2018 · PMID 29483060
Evidence scope. Human Phase 3b RCT with background SGLT2 inhibitor; exact start dose/route/frequency but disease- and therapy-specific.
GI adverse events were more common with dulaglutide, including nausea, diarrhea, and vomiting at 0.75 and 1.5 mg weekly.
Treatment-emergent adverse events were more common in patients treated with dulaglutide than in patients who received placebo, mainly because of an increased incidence of gastrointestinal adverse events.
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. The lancet. Diabetes & endocrinology · 2018 · PMID 29483060
Evidence scope. Human 24-week add-on trial; adverse-event rates are population and concomitant-therapy specific.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the
same as saying they are false — it marks where the evidence is missing.
Detailed mechanism: glucose-dependent insulin secretion, glucagon suppression, gastric slowing, and central appetite action. The selected exact-drug review establishes GLP-1 receptor agonism but not this entire bundle in one matched sentence.
Oral-contraceptive backup warning shown on the page. The page text itself attributes this warning to tirzepatide; no checked dulaglutide source supports transferring it.
Dose handling. no source dose, route, frequency, or formulation was changed.
Compounds. 20 (sections 01–20)
Unique verified PMIDs. 27
Claim-to-citation entries. 38
GAPs. 43
Live quote/metadata verification. 38/38 claim entries passed against NCBI EFetch XML during generation.
Post-write PMID spot-check. PASS — 8/8 spread PMIDs (15817669, 37062796, 10687883, 36615842, 39796530, 31542391, 18843002, 29483060) independently re-fetched; title, authors, journal, year, DOI, and quoted abstract sentence all matched live EFetch XML.
Parser check. PASS — a temporary batch-specific copy/input setup of `C:\\Users\\james\\onepin-library\\scripts\\build-citations.mjs` returned: `citations.json: 20 compounds, 38 claim entries from 27 unique papers, 43 GAPs`.